Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Abstract

Tanespimycin (17-allylamino-17-demethoxygeldanamycin, 17-AAG) disrupts heat shock protein 90 (HSP90), a key molecular chaperone for signal transduction proteins critical to myeloma growth, survival and drug resistance. In previous studies, tanespimycin monotherapy was well tolerated and active in heavily pretreated patients with relapsed/refractory multiple… (More)
DOI: 10.1111/j.1365-2141.2010.08264.x

Topics

Cite this paper

@article{Richardson2010TanespimycinWB, title={Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.}, author={Paul G Richardson and Ashraf Badros and Sundar Jagannath and Stefano R. Tarantolo and Jeffrey Wolf and Maher Albitar and David Berman and Marianne Messina and Kenneth C. Anderson}, journal={British journal of haematology}, year={2010}, volume={150 4}, pages={428-37} }